The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
GingerF
大力的灵雁
贪玩的秋柔
xzy998
Maestro_S
Riverchase
小太阳在营业
厨博士
wanci
海蓝云天
无极微光
乐空思
嘉心糖
科研girl
殷勤的紫槐
Semy
乐观秋荷
识字岭的岭
MMMMM
Xie
皖公网安备34019202002308
